Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons

2011 ◽  
pp. 9-13 ◽  
Author(s):  
Adeel A. Butt
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Immunodeficiency Virus

scholarly journals Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study

2019 ◽  
Vol 114 (5) ◽  
pp. 746-757 ◽  
Author(s):  
Richard K. Sterling ◽  
Abdus S. Wahed ◽  
Wendy C. King ◽  
David E. Kleiner ◽  
Mandana Khalili ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cohort Study ◽  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus ◽  
Immunodeficiency Virus

Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection

2020 ◽  
Vol 222 (5) ◽  
pp. 787-797 ◽  
Author(s):  
Thomas Krahn ◽  
Myriam Martel ◽  
Ruth Sapir-Pichhadze ◽  
Nadine Kronfli ◽  
Julian Falutz ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Confidence Interval ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Incident Diabetes ◽  
Comorbid Conditions ◽  
Nonalcoholic Fatty Liver ◽  
Immunodeficiency Virus

Abstract Background Cardiovascular and liver disease are main causes of death in people with human immunodeficiency virus (HIV) (PWH). In HIV-uninfected patients, nonalcoholic fatty liver disease (NAFLD) is associated with incident metabolic complications. We investigated the effect of NAFLD on development of metabolic comorbid conditions in PWH. Methods We included PWH undergoing a screening program for NAFLD using transient elastography. NAFLD was defined as a controlled attenuation parameter ≥248 dB/m with exclusion of other liver diseases. Incident diabetes, hypertension, dyslipidemia, and chronic kidney disease were investigated using survival analysis and Cox proportional hazards. Results The study included 485 HIV-monoinfected patients. During a median follow-up of 40.1 months (interquartile range, 26.5–50.7 months), patients with NAFLD had higher incidences of diabetes (4.74 [95% confidence interval, 3.09–7.27] vs 0.87 [.42–1.83] per 100 person-years) and dyslipidemia (8.16 [5.42–12.27] vs 3.99 [2.67–5.95] per 100 person-years) than those without NAFLD. With multivariable analysis, NAFLD was an independent predictor of diabetes (adjusted hazard ratio, 5.13; 95% confidence interval, 2.14–12.31) and dyslipidemia (2.35; 1.34–4.14) development. Conclusions HIV-monoinfected patients with NAFLD are at higher risk of incident diabetes and dyslipidemia. Early referral strategies and timely management of metabolic risk may improve outcomes.

scholarly journals Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Cecilia T. Costiniuk ◽  
Laurence Brunet ◽  
Kathleen C. Rollet-Kurhajec ◽  
Curtis L. Cooper ◽  
Sharon L. Walmsley ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Longitudinal Study ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Tobacco Smoking ◽  
Cohort Analysis ◽  
Tobacco Exposure ◽  
Immunodeficiency Virus ◽  
Significant Liver Fibrosis

Abstract Background.  Tobacco smoking has been shown to be an independent risk factor for liver fibrosis in hepatitis C virus (HCV) infection in some cross-sectional studies. No longitudinal study has confirmed this relationship, and the effect of tobacco exposure on liver fibrosis in human immunodeficiency virus (HIV)-HCV coinfected individuals is unknown. Methods.  The study population consisted of participants from the Canadian Co-infection Cohort study (CTN 222), a multicenter longitudinal study of HIV-HCV coinfected individuals from 2003 to 2014. Data were analyzed for all participants who did not have significant fibrosis or end-stage liver disease (ESLD) at baseline. The association between time-updated tobacco exposure (ever vs nonsmokers and pack-years) and progression to significant liver fibrosis (defined as an aspartate-to-platelet ratio index [APRI] ≥1.5) or ESLD was assessed by pooled logistic regression. Results.  Of 1072 participants included in the study, 978 (91%) had ever smoked, 817 (76%) were current smokers, and 161 (15%) were previous smokers. Tobacco exposure was not associated with accelerated progression to significant liver fibrosis nor with ESLD when comparing ever vs never smokers (odds ratio [OR] = 1.06, 95% confidence interval [CI], 0.43–1.69 and OR = 1.20, 95% CI, 0.21–2.18, respectively) or increases in pack-years smoked (OR = 1.05, 95% CI, 0.97–1.14 and OR = 0.94, 95% CI, 0.83–1.05, respectively). Both time-updated alcohol use in the previous 6 months and presence of detectable HCV ribonucleic acid were associated with APRI score ≥1.5. Conclusions.  Tobacco exposure does not appear to be associated with accelerated progression of liver disease in this prospective study of HIV-HCV coinfected individuals.

scholarly journals Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus

2001 ◽  
Vol 33 (10) ◽  
pp. 1793-1795 ◽  
Author(s):  
Vincent Soriano ◽  
Luz Martín‐Carbonero ◽  
Javier García‐Samaniego ◽  
Massimo Puoti
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Immunodeficiency Virus

scholarly journals Human immunodeficiency virus and liver disease: Conference proceedings

Hepatology ◽  
2010 ◽  
Vol 51 (3) ◽  
pp. 1046-1054 ◽  
Author(s):  
Kenneth E. Sherman ◽  
Vincent Soriano ◽  
Raymond T. Chung
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Conference Proceedings ◽  
Immunodeficiency Virus

Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease

2005 ◽  
Vol 20 (5) ◽  
pp. 739-745 ◽  
Author(s):  
MATHIAS LICHTERFELD ◽  
SUSANNE HAAS ◽  
HANS-PETER FISCHER ◽  
ESTER VOIGT ◽  
JURGEN K ROCKSTROH ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Hepatitis ◽  
Fatal Liver ◽  
Liver Histopathology ◽  
Immunodeficiency Virus
Sign in / Sign up

Export Citation Format

Share Document